What did the anchored MAIC of EPCORE FL-1 and inMIND show when comparing epcoritamab-R² with tafasitamab-R² in R/R follicular lymphoma?
Tafasitamab-R² was superior for overall response and time to next treatment, with no meaningful difference in complete response rates.
Epcoritamab-R² was superior across efficacy outcomes, including overall response (93% vs 81%), complete metabolic response rate and duration, and time to next treatment; safety was not assessed, and epcoritamab-R² is associated with more adverse events.
The two regimens showed equivalent efficacy and safety, so the choice can be based on cost alone.